Upcoming webinar

New data. Better insight. The future of precision breast cancer management.

Date: Tuesday, March 24, 2026

Time: 8:00 AM PT | 11:00 AM ET

Registrants will receive a recording of the webinar approximately one week after the event.

Join us for a KOL-led focused review highlighting three of the twelve studies presented at the recent San Antonio Breast Cancer Symposium (SABCS).

This virtual program will review and discuss findings from:

PALLAS (Signatera™ Genome)¹: Record-High Prognostic Performance in HR+/HER2- Early Breast Cancer
Signatera™ Genome: Strong Prognostic Performance Beyond Imaging
LEADER: MRD-Guided Insights in HR+ Early Breast Cancer

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers

Fenting Yan, MD, PhD

Dr. Fengting Yan, MD, PhD is a medical oncologist and Clinical Associate Professor at Fred Hutchinson Cancer Center and the University of Washington School of Medicine. She specializes in breast and gynecologic cancers, with a focus on translational research and personalized cancer care. Dr. Yan completed her hematology-oncology fellowship at Fred Hutch/University of Washington and is board certified in internal medicine, hematology, and medical oncology. She is widely recognized for her patient-centered approach and leadership in women’s cancer care.

Jamie E. McKenzie, MD

Dr. McKenzie is a fellowship-trained hematologist-oncologist who practiced at Tampa General Hospital, with prior training at Massachusetts General Hospital and Dana-Farber Cancer Institute. She is widely known for her multidisciplinary, holistic approach to breast cancer care, particularly for younger women, and brings a medical oncology perspective on how to align systemic therapy decisions with surgical management.

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy